Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-20 22:30 |
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Effici…
|
English | 68.5 KB | ||
| 2024-06-12 22:30 |
Cellectis dévoile une approche de thérapie génique non-virale pour traiter la d…
|
French | 177.1 KB | ||
| 2024-06-12 22:30 |
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in …
|
English | 156.6 KB | ||
| 2024-06-05 22:30 |
Monthly information on share capital and company voting rights
|
English | 91.0 KB | ||
| 2024-06-05 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 119.3 KB | ||
| 2024-06-04 22:30 |
Cellectis obtient la désignation de médicament orphelin pour son produit CAR T …
|
French | 197.2 KB | ||
| 2024-06-04 22:30 |
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Pr…
|
English | 66.3 KB | ||
| 2024-05-29 22:30 |
L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024
|
French | 125.6 KB | ||
| 2024-05-29 22:30 |
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
|
English | 151.7 KB | ||
| 2024-05-28 22:30 |
Cellectis Reports Financial Results for First Quarter 2024
|
English | 301.4 KB | ||
| 2024-05-28 22:30 |
Cellectis publie ses résultats financiers du premier trimestre 2024
|
French | 318.6 KB | ||
| 2024-05-27 22:30 |
Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai…
|
French | 178.5 KB | ||
| 2024-05-27 22:30 |
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
|
English | 182.4 KB | ||
| 2024-05-16 22:30 |
Monthly information on share capital and company voting rights
|
English | 91.1 KB | ||
| 2024-05-16 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 119.7 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
